

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Oxonic Acid-¹³C₂, ¹⁵N₃ (potassium salt hydrate)

Item No. 33282

Formal Name: 4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-

carboxylate- $4,6^{-13}$ C₂- $1,3,5^{-15}$ N₃

Synonyms:

Allantoxanic Acid- 13 C₂, 15 N₃, Potassium oxonate- 13 C₂, 15 N₃ C₂[13 C]₂H₂[15 N]₃O₄ • K [XH₂O] MF:

FW: 161.0 **Purity:** ≥95% Supplied as: A solid Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Oxonic acid- $^{13}C_2$, $^{15}N_3$ (potassium salt hydrate) is supplied as a solid. A stock solution may be made by dissolving the oxonic acid-13C2, 15N3 (potassium salt hydrate) in the solvent of choice, which should be purged with an inert gas. Oxonic acid-13C₂, 15N₃ (potassium salt hydrate) is slightly soluble in water.

Description

Oxonic acid-13C₂,15N₃ is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) (Item No. 22586) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC₅₀ = 0.8 μ M) that prevents metabolism and excretion of uric acid. 1.2 It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil (5-FU; Item No. 14416) in Yoshida sarcoma cell extracts with an IC_{50} value of 3.7 μ M.³ Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur (Item No. 26076) and uracil (Item No. 26088) without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents.⁴ Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.

References

- 1. Johnson, W.J. and Chartrand, A. Allantoxanamide: A potent new uricase inhibitor in vivo. Life Sci. 23(22), 2239-2244 (1978).
- 2. Gralla, E.J. and Crelin, E.S. Oxonic acid and fetal development: I. Embryotoxicity in mice. Toxicology 6(3), 289-297 (1976).
- 3. Shirasaka, T., Shimamoto, Y., and Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53(17), 4004-4009 (1993).
- 2. Stavric, B. and Nera, E.A. Use of the uricase-inhibited rat as an animal model in toxicology. Clin. Toxicol. 13(1), 47-74 (1978).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 03/09/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM